M M Borner
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Borner M, Roth A, Lanz D, Brauchli P, Honegger H, Köberle D, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8.
Feb 1, 2005A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Feb 1, 2005Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005; 16:282-8
Borner M M, Roth A D, Lanz D, Brauchli P, Honegger H, Köberle Dieter, Herrmann R, Rauch D, Saletti P, Wernli M, Popescu R, Dietrich D, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland
Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K, Borner M, Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21.
Aug 1, 2003Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
Aug 1, 2003Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003; 14:1215-21
Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann Beat, Goldhirsch A, Brunner K W, Borner M M, Swiss Group for Clinical Cancer Research (SAKK)